دورية أكاديمية
Antifungal Drug Usage in European Neonatal Units: A Multicenter Weekly Point Prevalence Study.
| العنوان: | Antifungal Drug Usage in European Neonatal Units: A Multicenter Weekly Point Prevalence Study. |
|---|---|
| المؤلفون: | Chorafa E; From the Infectious Diseases Unit, 3rd Department of Pediatrics, Aristotle University School of Medicine, Hippokration Hospital, Thessaloniki, Greece., Iosifidis E; From the Infectious Diseases Unit, 3rd Department of Pediatrics, Aristotle University School of Medicine, Hippokration Hospital, Thessaloniki, Greece., Oletto A; Fondazione Penta ETS, Padova, Italy., Warris A; Medical Research Council Center for Medical Mycology, University of Exeter, Exeter, United Kingdom.; European Pediatric Mycology Network., Castagnola E; European Pediatric Mycology Network.; Pediatric Infectious Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy., Bruggemann R; European Pediatric Mycology Network.; Department of Pharmacy, Centre of Expertise in Mycology Radboudumc/Canisius-Wilhelmina Hospital, Radboud University Medical Center, Nijmegen, The Netherlands., Groll AH; European Pediatric Mycology Network.; Infectious Disease Research Program, Center for Bone Marrow Transplantation, Department of Pediatric Hematology/Oncology, University Children's Hospital, Muenster, Germany., Lehrnbecher T; European Pediatric Mycology Network.; Division of Hematology, Oncology and Hemostaseology, Department of Pediatrics, Goethe University Frankfurt, Frankfurt/Main, Germany., Ferreras Antolin L; Medical Research Council Center for Medical Mycology, University of Exeter, Exeter, United Kingdom.; European Pediatric Mycology Network.; Pediatric Infectious Diseases and Immunology Unit, St George's University Hospitals, NHS Foundation Trust, London, United Kingdom., Mesini A; European Pediatric Mycology Network.; Pediatric Infectious Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy., Agakidou E; 1st Department of Neonatology and Intensive Care Unit, Aristotle University School of Medicine, Hippokration Hospital, Thessaloniki, Greece., Controzzi T; Pediatric Department, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy., De Luca M; Infectious Disease Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy., Dimitriou G; Department of Pediatrics, University General Hospital of Patras, Medical School, University of Patras, Rio, Greece., Emonts M; Paediatric Immunology, Infectious Diseases & Allergy Department Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom., Esposito S; Pediatric Department, Azienda Ospedaliera-Universitaria di Parma, Parma, Italy., Fernàndez-Polo A; Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain., Ghimenton-Walters E; Paediatric Immunology, Infectious Diseases & Allergy Department Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom., Gkentzi D; Department of Pediatrics, University General Hospital of Patras, Medical School, University of Patras, Rio, Greece., Grasa C; Pediatric Department, Hospital Universitario La Paz, IdiPAZ. CIBERINFEC, Madrid, Spain., Hatzidaki E; Pediatric Department, University General Hospital of Heraklion, Medical School, University of Crete, Heraklion, Greece., Jõgi P; Neonatology Department, Tartu University Hospital, Tartu, Estonia., Kildonaviciute K; Pediatric Department, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Kontou A; 1st Department of Neonatology and Intensive Care Unit, Aristotle University School of Medicine, Hippokration Hospital, Thessaloniki, Greece., Leibold-Aguinarte A; Division of Hematology, Oncology and Hemostaseology, Department of Pediatrics, Goethe University Frankfurt, Frankfurt/Main, Germany., Manzanares A; Neonatology Department, Hospital 12 de Octubre, Madrid, Spain., Mendoza-Palomar N; Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain., Metsvaht T; Neonatology Department, Tartu University Hospital, Tartu, Estonia., Noni M; 1st Department of Pediatrics, National and Kapodistrian University of Athens, 'Agia Sophia' Children's Hospital, Athens, Greece., Paulus S; Pediatric Department, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Perrone S; Pediatric Department, Azienda Ospedaliera-Universitaria di Parma, Parma, Italy., Rincón-López E; Neonatology Department, Hospital Gregorio Marañón, Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain., Romani L; Infectious Disease Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy., Sánchez L; Pediatric Department, Hospital Universitario La Paz, IdiPAZ. CIBERINFEC, Madrid, Spain., Cetin BS; Department of Pediatric Infectious Diseases, Faculty of Medicine, Erciyes University, Kayseri, Turkey., Spoulou V; 1st Department of Pediatrics, National and Kapodistrian University of Athens, 'Agia Sophia' Children's Hospital, Athens, Greece., Strenger V; Pediatric Department, Medical University Graz, Graz Austria., Vergadi E; Pediatric Department, University General Hospital of Heraklion, Medical School, University of Crete, Heraklion, Greece., Villaverde S; Neonatology Department, Hospital 12 de Octubre, Madrid, Spain., Vuerich M; Pediatric Department, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy., Zamora-Flores E; Neonatology Department, Hospital Gregorio Marañón, Madrid, Spain., Roilides E; From the Infectious Diseases Unit, 3rd Department of Pediatrics, Aristotle University School of Medicine, Hippokration Hospital, Thessaloniki, Greece.; 1st Department of Neonatology and Intensive Care Unit, Aristotle University School of Medicine, Hippokration Hospital, Thessaloniki, Greece. |
| المصدر: | The Pediatric infectious disease journal [Pediatr Infect Dis J] 2024 Jun 25. Date of Electronic Publication: 2024 Jun 25. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Williams & Wilkins Country of Publication: United States NLM ID: 8701858 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-0987 (Electronic) Linking ISSN: 08913668 NLM ISO Abbreviation: Pediatr Infect Dis J Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Baltimore, Md. : Williams & Wilkins, c1987- |
| مستخلص: | Background: Data on antifungal prescribing in neonatal patients are limited to either single-center or single-country studies or to 1-day recording. Therefore, we assessed antifungal longitudinal usage in neonatal units (NUs) within Europe. Methods: CALYPSO, a prospective weekly point prevalence study on antifungal drug usage in NUs in 18 hospitals (8 European countries), was conducted in 2020 during a 12-week period. All patients receiving systemic antifungals were included. Ward demographics were collected at the beginning; ward and patient data including indication, risk factors and antifungal regimen were weekly collected prospectively. Results: Among 27 participating NUs, 15 (56%) practiced antifungal prophylaxis for neonates with birth weight <1000 g or <1500 g and additional risk factors. In total, 174 patients received antifungals with a median frequency per week of 10.5% ranging from 6.9% to 12.6%. Indication for antifungal prescribing was prophylaxis in 135/174 (78%) courses and treatment in 22% [39 courses (69% empirical, 10% preemptive, 21% targeted)]. Fluconazole was the most frequent systemic agent used both for prophylaxis (133/135) and treatment (15/39, 39%). Among neonates receiving prophylaxis, the most common risk factors were prematurity (119/135, 88%), mechanical ventilation (109/135, 81%) and central vascular catheters (89/135, 66%). However, gestational age <28 weeks was only recorded in 55/135 (41%) courses and birth weight <1000 g in 48/135 (35%). Most common reason for empirical treatment was late-onset sepsis; all 8 targeted courses were prescribed for invasive candidiasis. Conclusion: Antifungal usage in European NUs is driven by prophylaxis and empirical treatment with fluconazole being the most prescribed agent for both indications. Competing Interests: E.C.: Speaker at sponsored symposia for Pfizer and F2G. C.G. is funded by the Spanish Ministry of Science and Innovation—Instituto de Salud Carlos III and Fondos FEDER (Contrato Juan Rodés JR22/00044). A.H.G. has received grants from Gilead, Merck, Sharp & Dohme and Pfizer and has served as a consultant to Amplyx, Astellas, Basilea, F2G, Gilead. Merck, Sharp & Dohme, Pfizer, Scynexis and Mundipharma. T.L. has received a grant from Gilead Sciences, has served as a consultant to Gilead Sciences, Merck/MSD, Pfizer, Astellas, AstraZeneca, Recordati and Roche and served at the speaker´s bureau of Gilead Sciences, Merck/MSD, Astellas, Pfizer and GSK and Recordati. E.R. has received research grants from Merck, Abvie, Shionogi, Cidara and Pfizer Inc. to his institution and is a scientific advisor and member of the speaker bureaux for Gilead, Merck, Shionogi, Mundipharma and Pfizer Inc. For the remaining authors, there are no conflicts of interest to disclose. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.) |
| References: | Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41:1232–1239. Zaoutis TE, Heydon K, Localio R, et al. Outcomes attributable to neonatal candidiasis. Clin Infect Dis. 2007;44:1187–1193. Steinbach WJ, Roilides E, Berman D, et al.; International Pediatric Fungal Network. Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J. 2012;31:1252–1257. Pana ZD, Roilides E, Warris A, et al. Epidemiology of invasive fungal disease in children. J Pediatric Infect Dis Soc. 2017;6:S3–S11. Walsh TJ, Katragkou A, Chen T, et al. Invasive candidiasis in infants and children: recent advances in epidemiology, diagnosis, and treatment. J Fungi (Basel). 2019;5:11. Benedict K, Roy M, Kabbani S, et al. Neonatal and pediatric candidemia: results from population-based active laboratory surveillance in four US locations, 2009-2015. J Pediatric Infect Dis Soc. 2018;7:e78–e85. Warris A, Pana ZD, Oletto A, et al.; EUROCANDY Study Group. Etiology and outcome of candidemia in neonates and children in Europe: an 11-year multinational retrospective study. Pediatr Infect Dis J. 2020;39:114–120. Benjamin DK, Stoll BJ, Gantz MG, et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics. 2010;126:865–873. Shetty SS, Harrison LH, Hajjeh RA, et al. Determining risk factors for candidemia among newborn infants from population-based surveillance: Baltimore, Maryland, 1998-2000. Pediatr Infect Dis J. 2005;24:601–604. Yu Y, Du L, Yuan T, et al. Risk factors and clinical analysis for invasive fungal infection in neonatal intensive care unit patients. Am J Perinatol. 2013;30:589–594. Ferreras-Antolín L, Irwin A, Atra A, et al. Neonatal antifungal consumption is dominated by prophylactic use; outcomes from the pediatric antifungal stewardship: optimizing antifungal prescription study. Pediatr Infect Dis J. 2020;38:1219–1223. Lestner JM, Versporten A, Doerholt K, et al.; ARPEC Project Group. Systemic antifungal prescribing in neonates and children: outcomes from the antibiotic resistance and prescribing in European children (ARPEC) study. Antimicrob Agents Chemother. 2015;59:782–789. Stultz JS, Kohinke R, Pakyz AL. Variability in antifungal utilization among neonatal, pediatric, and adult inpatients in academic medical centers throughout the United States of America. BMC Infect Dis. 2018;18:1–9. Goldman JL, Ross RK, Lee BR, et al. Variability in antifungal and antiviral use in hospitalized children. Infect Control Hosp Epidemiol. 2017;38:743–746. Mendoza-Palomar N, Garcia-Palop B, Melendo S, et al. Antifungal stewardship in a tertiary care paediatric hospital: the PROAFUNGI study. BMC Infect Dis. 2021;21:1–7. Kaur H, Krishnamoorthi S, Dhaliwal N, et al. Antifungal prescription practices and consumption in a tertiary care hospital of a developing country. Mycoses. 2022;65:935–945. Ferreras-Antolín L, Irwin A, Atra A, et al. Pediatric antifungal prescribing patterns identify significant opportunities to rationalize antifungal use in children. Pediatr Infect Dis J. 2022;41:e69–e74. Çağlar I, Devrim I, Ozdemir Z, et al. Antifungal consumption, indications and selection of antifungal drugs in paediatric tertiary hospitals in Turkey: results from the first national point prevalence survey. J Glob Antimicrob Resist. 2018;15:232–238. Ferreras-Antolin L, Bielicki J, Warris A, et al.; GARPEC Network. Global divergence of antifungal prescribing patterns: data from the global antimicrobial resistance, prescribing, and efficacy in neonates and children surveys. Pediatr Infect Dis J. 2021;40:327–332. Hope WW, Catagnola E, Groll AH, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect. 2012;18:38–52. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2015;62:e1–e50. Leonart LP, Stumpf Tonin F, Ferreira VL, et al. Fluconazole doses used for prophylaxis of invasive fungal infection in neonatal intensive care units: a network meta-analysis. J Pediatr. 2017;185:129–135. Ferreras-Antolín L, Sharland M, Warris A. Management of invasive fungal disease in neonates and children. Pediatr Infect Dis J. 2019;38:2–6. Kourti M, Chorafa E, Roilides E, et al. Antifungal stewardship programs in children: challenges and opportunities. Pediatr Infect Dis J. 2023;42:e246–e248. Turner K, Manzoni P, Benjamin DK, et al. Fluconazole loading dose pharmacokinetics and safety in infants. Curr Med Chem. 2012;19:4617–4620. Piper L, Smith PB, Hornik CP, et al. Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Dis J. 2011;30:375–378. Hope WW, Smith PB, Buell AA, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother. 2010;54:2633–2637. |
| تواريخ الأحداث: | Date Created: 20240625 Latest Revision: 20240625 |
| رمز التحديث: | 20240626 |
| DOI: | 10.1097/INF.0000000000004445 |
| PMID: | 38917027 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1532-0987 |
|---|---|
| DOI: | 10.1097/INF.0000000000004445 |